OXYGENTA PHARMACEUTICAL
|
OXYGENTA PHARMACEUTICAL Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -4.75 | -2.78 | -1.04 | -8.15 | -0.43 |
| CEPS(Rs) | -4.12 | -1.81 | -0.24 | -6.70 | 0.69 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | -11.54 | -6.93 | -6.18 | -32.53 | -24.38 |
| Tax Rate(%) | 20.78 | 28.24 | 74.92 | -1.74 | -24.75 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -13.55 | -8.98 | -24.46 | -22.97 | 2.44 |
| EBIT Margin(%) | -15.35 | -11.09 | -30.97 | -31.90 | 0.72 |
| Pre Tax Margin(%) | -19.63 | -13.13 | -34.99 | -36.70 | -0.81 |
| PAT Margin (%) | -15.55 | -9.42 | -8.78 | -37.34 | -1.01 |
| Cash Profit Margin (%) | -13.50 | -6.12 | -2.06 | -30.72 | 1.62 |
| Performance Ratios | |||||
| ROA(%) | -20.42 | -16.57 | -6.40 | -27.09 | -1.88 |
| ROE(%) | - | - | - | - | - |
| ROCE(%) | -33.53 | -32.89 | -41.69 | -50.32 | 3.18 |
| Asset Turnover(x) | 1.31 | 1.76 | 0.73 | 0.73 | 1.86 |
| Sales/Fixed Asset(x) | 1.66 | 1.95 | 0.82 | 0.75 | 1.79 |
| Working Capital/Sales(x) | -3.26 | -1.99 | -4.13 | -3.93 | 40.46 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.60 | 0.51 | 1.22 | 1.34 | 0.56 |
| Receivable days | 24.43 | 20.80 | 80.66 | 69.12 | 9.61 |
| Inventory Days | 80.66 | 57.15 | 117.03 | 111.83 | 58.49 |
| Payable days | 140.38 | 99.66 | 254.01 | 229.85 | 78.25 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -11.73 | -44.02 | -118.58 | -5.46 | 34.82 |
| Price/Book(x) | -4.19 | -11.48 | -4.69 | -1.13 | -0.99 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 2.53 | 3.26 | 3.89 | 3.87 | 1.42 |
| EV/Core EBITDA(x) | -19.06 | -41.90 | -15.97 | -16.88 | 58.17 |
| EV/EBIT(x) | -16.51 | -29.40 | -12.56 | -12.13 | 197.73 |
| EV/CE(x) | 4.28 | 9.74 | 4.16 | 5.50 | 2.76 |
| M Cap / Sales | 1.58 | 2.69 | 2.45 | 1.68 | 0.56 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.37 | 175.71 | 27.93 | -48.80 | 16.33 |
| Core EBITDA Growth(%) | -76.64 | 11.90 | -35.99 | -579.49 | -62.36 |
| EBIT Growth(%) | -43.13 | 1.29 | -24.20 | -2,369.43 | -91.16 |
| PAT Growth(%) | -70.63 | -195.99 | 69.93 | -1,795.44 | -120.84 |
| EPS Growth(%) | -70.62 | -167.98 | 87.25 | -1,795.29 | -114.97 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | -2.57 | -2.43 | -2.77 | -1.47 | -1.51 |
| Current Ratio(x) | 0.60 | 0.36 | 0.72 | 0.76 | 1.19 |
| Quick Ratio(x) | 0.26 | 0.12 | 0.31 | 0.40 | 0.28 |
| Interest Cover(x) | -3.59 | -5.43 | -7.70 | -6.65 | 0.47 |
| Total Debt/Mcap(x) | 0.61 | 0.21 | 0.59 | 1.31 | 1.53 |
Compare Financial Ratios of peers of OXYGENTA PHARMACEUTICAL
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| OXYGENTA PHARMACEUTICAL | ₹198.3 Cr | 6.4% | 15.9% | -51% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -0.1% | 0.5% | 14% | Stock Analytics | |
| DIVIS LABORATORIES | ₹218,972.0 Cr | -0.9% | 21.1% | 25.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,358.0 Cr | -1.3% | 1.1% | 32.7% | Stock Analytics | |
| CIPLA | ₹118,916.0 Cr | 0.2% | 2.1% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,824.0 Cr | 0.2% | -7.7% | -7.5% | Stock Analytics | |
OXYGENTA PHARMACEUTICAL Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| OXYGENTA PHARMACEUTICAL | 6.4% |
15.9% |
-51% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
You may also like the below Video Courses
